» Articles » PMID: 38671369

Ginsenoside Rh2 Shifts Tumor Metabolism from Aerobic Glycolysis to Oxidative Phosphorylation Through Regulating the HIF1-α/PDK4 Axis in Non-small Cell Lung Cancer

Overview
Journal Mol Med
Publisher Biomed Central
Date 2024 Apr 26
PMID 38671369
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Ginsenoside Rh2 (G-Rh2), a steroidal compound extracted from roots of ginseng, has been extensively studied in tumor therapy. However, its specific regulatory mechanism in non-small cell lung cancer (NSCLC) is not well understood. Pyruvate dehydrogenase kinase 4 (PDK4), a central regulator of cellular energy metabolism, is highly expressed in various malignant tumors. We investigated the impact of G-Rh2 on the malignant progression of NSCLC and how it regulated PDK4 to influence tumor aerobic glycolysis and mitochondrial function.

Method: We examined the inhibitory effect of G-Rh2 on NSCLC through I proliferation assay, migration assay and flow cytometry in vitro. Subsequently, we verified the ability of G-Rh2 to inhibit tumor growth and metastasis by constructing subcutaneous tumor and metastasis models in nude mice. Proteomics analysis was conducted to analyze the action pathways of G-Rh2. Additionally, we assessed glycolysis and mitochondrial function using seahorse, PET-CT, Western blot, and RT-qPCR.

Result: Treatment with G-Rh2 significantly inhibited tumor proliferation and migration ability both in vitro and in vivo. Furthermore, G-Rh2 inhibited the tumor's aerobic glycolytic capacity, including glucose uptake and lactate production, through the HIF1-α/PDK4 pathway. Overexpression of PDK4 demonstrated that G-Rh2 targeted the inhibition of PDK4 expression, thereby restoring mitochondrial function, promoting reactive oxygen species (ROS) accumulation, and inducing apoptosis. When combined with sodium dichloroacetate, a PDK inhibitor, it complemented the inhibitory capacity of PDKs, acting synergistically as a detoxifier.

Conclusion: G-Rh2 could target and down-regulate the expression of HIF-1α, resulting in decreased expression of glycolytic enzymes and inhibition of aerobic glycolysis in tumors. Additionally, by directly targeting mitochondrial PDK, it elevated mitochondrial oxidative phosphorylation and enhanced ROS accumulation, thereby promoting tumor cells to undergo normal apoptotic processes.

Citing Articles

Traditional Chinese medicine in lung cancer treatment.

Xi Z, Dai R, Ze Y, Jiang X, Liu M, Xu H Mol Cancer. 2025; 24(1):57.

PMID: 40001110 PMC: 11863959. DOI: 10.1186/s12943-025-02245-6.


Curcumin-Dichloroacetate Hybrid Molecule as an Antitumor Oral Drug against Multidrug-Resistant Advanced Bladder Cancers.

Gupta K, Taylor T, Panda S, Thangaraju M, Lokeshwar B Cancers (Basel). 2024; 16(17).

PMID: 39272966 PMC: 11394085. DOI: 10.3390/cancers16173108.

References
1.
Wang M, Herbst R, Boshoff C . Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021; 27(8):1345-1356. DOI: 10.1038/s41591-021-01450-2. View

2.
Spruijt L, Naviaux R, McGowan K, Nyhan W, Sheean G, Haas R . Nerve conduction changes in patients with mitochondrial diseases treated with dichloroacetate. Muscle Nerve. 2001; 24(7):916-24. DOI: 10.1002/mus.1089. View

3.
Michelakis E, Gurtu V, Webster L, Barnes G, Watson G, Howard L . Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients. Sci Transl Med. 2017; 9(413). DOI: 10.1126/scitranslmed.aao4583. View

4.
Liu J, Cai Q, Wang W, Lu M, Liu J, Zhou F . Ginsenoside Rh2 pretreatment and withdrawal reactivated the pentose phosphate pathway to ameliorate intracellular redox disturbance and promoted intratumoral penetration of adriamycin. Redox Biol. 2020; 32:101452. PMC: 7264470. DOI: 10.1016/j.redox.2020.101452. View

5.
Zhou W, Wu G, Huang J, Li J, Hao C, He Q . Low expression of PDK1 inhibits renal cell carcinoma cell proliferation, migration, invasion and epithelial mesenchymal transition through inhibition of the PI3K-PDK1-Akt pathway. Cell Signal. 2018; 56:1-14. DOI: 10.1016/j.cellsig.2018.11.016. View